AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home BIOCELL Article
PDF (30.3 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Article | Open Access

miR-122-5p Regulates Ferroptosis through Targeting the Glutamine Transporter SLC1A5 in Hepatocellular Carcinoma

Mingxuan Lei1, Jiayin Xu2, Xiaoying Hu2, Lin Feng3, Baoping Luo4,5,6( )
The Second Clinical Medical College, Beijing University of Chinese Medicine, Beijing, 100029, China
The First Clinical Medical College, Hubei University of Chinese Medicine, Wuhan, 430064, China
Department of Central Sterile Supply, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430060, China
Institute of Liver Diseases, Hubei Key Laboratory of Theoretical and Applied Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China
Hubei Shizhen Laboratory, Wuhan, 430061, China
Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, 430061, China
Show Author Information

Abstract

Background

Hepatocellular carcinoma (HCC) typically begins inconspicuously and progresses swiftly, leading to most patients being diagnosed at an advanced stage. Accordingly, a pressing priority is to clarify the development mechanisms of HCC and devise efficient intervention and treatment protocols.

Methods

An upstream miRNA of solute carrier transporter family 1 member 5 (SLC1A5) was predicted to be miR-122-5p by various databases, and a dual-luciferase reporter gene assay was used to verify the SLC1A5- and miR-122-5p-targeting relationship. SLC1A5 and miR-122-5p expression in HCC cells was quantitatively assessed using quantitative reverse transcription polymerase chain reaction (qRT–PCR). Western blotting was used to evaluate SLC1A5 expression in HCC cells. To determine the effects of the ferroptosis inducers erastin and L-g-glutamyl-p-nitroanilide (GPNA) on Huh-7 and HepG2 cell viability, a Cell Counting Kit-8 assay was performed. Additionally, various assay kits were used to assess malondialdehyde (MDA), Fe2+, and reactive oxygen species (ROS) levels in HCC cells. Moreover, an HCC tumor model was established in nude mice to investigate the growth of HCC tumors overexpressing miR-122-5p.

Results

miR-122-5p downregulated SLC1A5 levels. MiR-122-5p knockdown inhibited erastin-promoted ferroptosis, whereas miR-122-5p overexpression promoted ferroptosis. After knocking down miR-122-5p, the MDA, Fe2+, and ROS levels in Huh-7 and HepG2 cells decreased, whereas overexpressing miR-122-5p increased the MDA, Fe2+, and ROS levels. Following the addition of GPNA, the cells experienced decreased viability and increased MDA levels, which in turn inhibited ferroptosis. Knockdown of SLC1A5 partially reversed the ferroptosis-inhibiting effect induced by knocking down miR-122-5p. Additionally, the overexpression of miR-122-5p hindered HCC development in vivo.

Conclusion

miR-122-5p downregulates SLC1A5, which promotes lipid peroxidation and iron accumulation and inhibits glutamine transport, ultimately causing ferroptosis in HCC cells.

References

【1】
【1】
 
 
BIOCELL
Pages 1947-1965

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Lei M, Xu J, Hu X, et al. miR-122-5p Regulates Ferroptosis through Targeting the Glutamine Transporter SLC1A5 in Hepatocellular Carcinoma. BIOCELL, 2025, 49(10): 1947-1965. https://doi.org/10.32604/biocell.2025.068926

823

Views

23

Downloads

0

Crossref

1

Web of Science

0

Scopus

Received: 10 June 2025
Accepted: 26 August 2025
Published: 22 October 2025
© The Author 2024.

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.